Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Apollomics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
APLM
Nasdaq
8731
https://www.apollomicsinc.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Apollomics Inc
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
- Apr 25th, 2024 12:30 pm
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apr 10th, 2024 11:00 am
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apr 2nd, 2024 12:00 pm
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
- Mar 28th, 2024 11:00 am
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
- Mar 26th, 2024 12:00 pm
Apollomics Names Matthew Plunkett as Chief Financial Officer
- Mar 4th, 2024 3:18 pm
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
- Mar 4th, 2024 12:00 pm
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 7th, 2024 12:00 pm
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Jan 19th, 2024 9:15 pm
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
- Jan 17th, 2024 9:30 pm
Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment
- Jan 3rd, 2024 11:52 pm
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Jan 3rd, 2024 12:00 pm
Apollomics to Present at the 2024 Biotech Showcase
- Jan 2nd, 2024 9:30 pm
Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication
- Dec 7th, 2023 6:01 pm
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
- Dec 4th, 2023 12:00 pm
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Nov 29th, 2023 12:30 pm
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
- Nov 28th, 2023 12:00 pm
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
- Nov 16th, 2023 1:30 pm
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
- Oct 31st, 2023 12:30 pm
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
- Oct 26th, 2023 12:50 pm
Scroll